Roche completes enrollment in Herceptin SC Phase 3 trial for HER2-positive breast can

[News]

Halozyme Therapeutics, Inc. today announced that Roche has completed patient enrollment for the pivotal Phase 3 study of Herceptin SC (trastuzumab subcutaneous), a subcutaneous formulation that uses Halozyme's Enhanze™ technology (rHuPH20, recombinant human hyaluronidase).

More... (http://www.news-medical.net/news/20101207/Roche-completes-enrollment-in-Herceptin-SC-Phase-3-trial-for-HER2-positive-breast-cancer.aspx)